Market Research Logo

Global Myasthenia Gravis Drugs Market 2017-2021

Global Myasthenia Gravis Drugs Market 2017-2021

About Myasthenia Gravis Drugs

Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.

Technavio’s analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.Covered in this report

The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Flamel Technologies
  • F. Hoffmann-La Roche
  • Grifols
  • Pfizer
  • Shire
  • Valeant Pharmaceuticals
Other prominent vendors
  • Alexion Pharmaceuticals
  • Catalyst Pharmaceuticals
  • CSL
  • Curavac
  • Cytokinetics
  • Galencia
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis
Market driver
  • Approval of novel monoclonal antibodies
  • For a full, detailed list, view our report
Market challenge
  • Limited availability of approved drugs
  • For a full, detailed list, view our report
Market trend
  • Emergence of new entrants
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Myasthenia Gravis Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global myasthenia gravis drugs market: Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, and Valeant Pharmaceuticals

Other Prominent Vendors in the market are: Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, and Novartis

Commenting on the report, an analyst from Technavio’s team said: “The high unmet medical need in the market has driven the emergence of new entrants, which are extensively conducting R&D activities to bring new products to the market. For instance, Curavac, Novartis, Cytokinetics, and Catalyst Pharmaceuticals are few of the potential vendors that are anticipating new approvals during the forecast period. Curavac is currently investigating CVMG101, an immunotherapy, for the potential treatment of myasthenia gravis. The drug candidate is in Phase Ib development stage. CVMG101 already received orphan drug designation from the US FDA and European Medicines Agency (EMA) in 2011 and 2009, respectively. Therefore, the product has an added advantage in gaining approval soon.”

According to the report, myasthenia gravis is the common disorder of neuromuscular transmission. The presence of large patient pool with myasthenia gravis is expected to fuel the market growth. The data estimates suggest that out of the existing patient pool in the US, approximately 15%-20% of people will experience a myasthenic crisis (a complication of myasthenia gravis resulting in severe muscle weakness, leading to respiratory failure). Three-fourths of these cases experience their first crisis within two years of diagnosis. Further, the disease is increasingly affecting the pediatric population, which will, in turn, increase the overall patient pool, thereby fueling the market growth. For instance, the incidence in the pediatric population is estimated to be between 1 and 5 cases per million. It is further estimated that between 10% and 15% of the myasthenia gravis cases occur in the pediatric population. Such rising cases with myasthenia gravis will certainly drive the market growth.

Further, the report states that the growing preference for substitutes such as thymectomy could hinder the growth prospects in the market. Thymectomy is mandatory in individuals with thymoma and is recommended as an alternative for non-thymomatous individuals with generalized myasthenia gravis. Particularly in individuals with acetylcholine antibodies and younger than 60 years, to enhance the likelihood of remission or improvement. Thymectomy therapy offers long-term benefit to an individual by reducing or stopping the existing chronic medical therapies. In addition, there has been growing support from healthcare organizations to opt for thymectomy. For instance, in August 2016, in a global study of myasthenia gravis (partially funded by National Institutes of Health), researchers found that surgical removal of thymus reduced individual's weakness and their need for immunosuppressive drugs. On an average, the researchers stated that the combination of surgery and prednisone treatment minimized overall muscle weakness greater than prednisone treatment alone. Although surgery is associated with higher costs, it could reduce the length of hospitalization. Further, thymectomy rarely causes any adverse effects. This indicates that surgery would affect the adoption rates of existing drugs in the market.

Companies Mentioned

Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, Valeant Pharmaceuticals, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis.

  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Highlights
      • Table Key customer segments of global myasthenia gravis drugs market
      • Table Factors affecting the adoption rates of myasthenia gravis drugs market
  • Pipeline analysis
    • Table Key pipeline candidates
  • Market landscape
    • Global myasthenia gravis drugs market
      • Table Global myasthenia gravis drugs market snapshot
      • Table Analysis of global myasthenia gravis drugs market
      • Table Global myasthenia gravis drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis of global myasthenia gravis drugs market
      • Table Opportunity analysis in developed and emerging markets
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by therapy area
    • Table Segmentation of global myasthenia gravis drugs market by therapy
    • Anticholinesterases
    • Immunosuppressants
    • IVIg
  • Geographical segmentation
    • Table Segmentation of global myasthenia gravis drugs market based on geography 2016 and 2021
    • Table Global myasthenia gravis drugs market revenue by geography 2016-2021 ($ millions)
    • Myasthenia gravis drugs market in Americas
      • Table Market scenario in Americas
      • Table Myasthenia gravis drugs market in Americas 2016-2021 ($ millions)
    • Myasthenia gravis drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Myasthenia gravis drugs market in EMEA 2016-2021 ($ millions)
    • Myasthenia gravis drugs market in APAC
      • Table Market scenario in APAC
      • Table Myasthenia gravis drugs market in APAC 2016-2021 ($ millions)
      • Table Key drivers and challenges in APAC
  • Market drivers
    • Approval of novel monoclonal antibodies
      • Table Key pipeline monoclonal antibodies
    • High unmet medical need
      • Table Incidence data for myasthenia gravis (annually)
    • Growing research activities for the better understanding and diagnosis of myasthenia gravis
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Presence of substitutes
    • Limited availability of approved drugs
    • Lack of long-term commitment
      • Table Forcefield analysis of drivers and challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of new entrants
      • Table Key entrants in myasthenia gravis drugs market
    • Growing strategic acquisitions
      • Table Key acquisitions and their impact
    • Potential treatment options
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global myasthenia gravis drugs market 2015
      • Table Competitive analysis of global myasthenia gravis drugs market
      • Table Market penetration of various myasthenia gravis manufacturers 2015
  • Key vendor analysis
    • Flamel Technologies
      • Table Flamel Technologies: Key highlights
      • Table Flamel Technologies: Strength assessment
      • Table Flamel Technologies: Strategy assessment
      • Table Flamel Technologies: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
      • Table F. Hoffmann-La Roche: Year-over-year (YoY) growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue of CellCept 2013-2015 ($ millions)
    • Grifols
      • Table Grifols: Key highlights
      • Table Grifols: Strength assessment
      • Table Grifols: Strategy assessment
      • Table Grifols: Opportunity assessment
    • Pfizer
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
      • Table Pfizer: YoY and growth rate of Medrol 2013-2015 ($ millions)
    • Shire
      • Table Shire: Key highlights
      • Table Shire: Strength assessment
      • Table Shire: Strategy assessment
      • Table Shire: Opportunity assessment
    • Valeant Pharmaceuticals
      • Table Valeant Pharmaceuticals: Strength assessment
      • Table Valeant Pharmaceuticals: Strategy assessment
      • Table Valeant Pharmaceuticals: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report